What StemPoint Capital does

StemPoint Capital LP is a private investment firm founded in 2023 and headquartered at 520 Madison Avenue, 19th Floor, New York City. The firm is structured as a limited partnership and concentrates on the healthcare and life sciences sector, with a particular emphasis on identifying M&A opportunities within biotechnology. Interests in its fund are offered exclusively to qualified investors through a confidential offering memorandum and subscription documents, in line with standard private placement practice for hedge fund vehicles. The firm operates as a traditional investment manager rather than a technology company, and no named products, platforms, modules, or proprietary technology components are described in available material. Its core "product" is the generation and articulation of investment theses — for example, publicly pitching French biotech Abivax as an M&A target at the Sohn Montreal Investment Conference in June 2026 following a clinical trial setback, and broader commentary on accelerating biotech sector M&A activity.

The firm's go-to-market centers on high-touch, conference-driven LP engagement and sector thought leadership. Principal Michelle Ross has publicly articulated a bullish outlook for biotech M&A, and the firm has secured backing from Leucadia Asset Management, providing institutional credibility at inception. Its marketing footprint is concentrated in investment conferences as a top-of-funnel channel for sourcing qualified investors and validating ideas, rather than scaled digital distribution. The operating footprint is US-registered (New York), although deal and conference activity extends to Canada and Europe.

StemPoint's revenue model follows conventional hedge fund economics — management fees and/or performance fees on assets under management — though AUM and revenue are not publicly disclosed. The team is small (1-10 employees), consistent with an early-stage fund. The primary "customer" set comprises qualified institutional investors acting as limited partners; healthcare and biotech companies are addressed as investment targets and potential M&A counterparties rather than as direct paying customers. No patents, certifications, partnerships, subsidiaries, or regulatory actions are disclosed, and there is no indication of a parent company or institutional control structure beyond the Leucadia relationship.

Name

StemPoint Capital

Legal name

StemPoint Capital LP

Website

https://stempointcapital.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

StemPoint Capital LP is a New York-based private investment firm founded in 2023 that focuses on healthcare and life sciences, identifying biotech M&A opportunities for qualified institutional investors and pitching theses at industry conferences.

Ownership category

akta.pro rank

Product category

Healthcare & Biotech Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Biotech investment management
• Healthcare sector investing
• Biotech M&A advisory
• Life sciences hedge fund
• Pharmaceutical investment research

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Marketing channels1 record

Core offering

StemPoint Capital operates a private investment fund (StemPoint Capital LP) that invests in the healthcare, biotechnology, and life sciences sector, with a particular focus on identifying biotech M&A targets. The firm exploits the growth characteristics of biotechnology alongside the protective attributes of the pharmaceutical sector, and surfaces investment ideas to qualified investors at industry conferences and through private placement offerings.

Product overview

StemPoint Capital is a hedge fund/investment firm that focuses on the healthcare and life sciences sector. The firm identifies and pitches investment opportunities, including M&A targets in biotech, to institutional investors at conferences such as the Sohn Montreal Investment Conference. Based on available source material, no specific named products, modules, or platform offerings are described — the firm appears to operate as a traditional investment management entity rather than a product-based technology company.

Differentiator

Problem solved

Functional benefit

Products and services

• StemPoint Capital Fund (LP Interests) Private investment fund (StemPoint Capital LP) focused on the healthcare, biotechnology, and life sciences sector, made available only to qualified investors through a confidential offering memorandum and subscription documents; exploits the growth characteristics of biotech and the protective attributes of the pharmaceutical sector.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Peers

• Deerfield Management:

Direct peers

• Perceptive Advisors: Healthcare-focused hedge fund manager with deep biotech and life sciences expertise. Directly comparable to StemPoint in sector specialization and event-driven biotech investing approach.
• RA Capital Management: Healthcare and biotech-focused crossover investment fund with both public-equity and private investment capabilities. Directly comparable to StemPoint in its specialized healthcare focus and event-driven biotech positioning.
• Baker Bros. Advisors: One of the largest dedicated biotech-focused investment firms, taking concentrated long positions in life sciences equities. Directly comparable to StemPoint in its single-sector healthcare focus and fundamental-driven biotech investing.
• Orbimed Advisors: Leading healthcare-dedicated investment firm with multi-strategy public and private equity funds. Directly comparable to StemPoint in vertical specialization across biotech and pharmaceuticals.
• EcoR1 Capital: Biotech-focused investment firm taking concentrated long positions in clinical-stage biotechnology. Directly comparable to StemPoint in narrow sector specialization and fundamental biotech research approach.
• Cormorant Asset Management: Healthcare-focused investment manager investing across public biotech equities and private healthcare companies. Directly comparable to StemPoint in dedicated healthcare focus and biotech M&A thesis.
• Sectoral Asset Management: Global healthcare-focused equity manager specializing in biotech and pharmaceutical equities. Directly comparable to StemPoint in single-sector healthcare concentration and fundamental biotech investing.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemPoint Capital